Issam Ben-Sahra

Issam (2011_issam.jpg)

Postdoctoral Fellow:

2011 -

Education:

Ph.D. 2010, University of Sophia Antipolis, Nice, France

Research Interest:

Issam is interested in understanding the impact of mTOR-stimulated metabolic pathways on the properties of cells and tumors with specific upstream oncogenic events.  He is focused on revealing how metabolic changes common to tumor cells can differentiate them from their tissue of origin, with a focus on revealing novel therapeutic opportunities.

Publications:

Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T. The TSC-mTOR pathway regulates macrophage polarization. Nat Commun. 2013. 4: 2834. PMID: 24280772

Howell JJ, Ricoult SJ, Ben-Sahra IManning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans. 2013. 41(4):906-12. PMID: 23863154

Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H, Asnafi V, Pontier-Bres R, Reverso J, Michiels JF, Ben Sahra I, Bost F, Peyron JF. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett. 336(1): 114-26. PMID: 23612073

Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ. 2013. 20(4): 611-9. PMID: 23238567

Ben-Sahra I*, Howell JJ*, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013. 339(6125): 1323-8. PMID: 23429703. *Co-1st authors.

Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol. 2012. 4(4): 207-20. PMID: 22467682

Bost F, Ben-Sahra I, Tanti JF. Prevention of mutagenesis: new potential mechanisms of metformin action in neoplastic cells. Cancer Prev Res (Phila). 2012. 5(4): 503-6. PMID: 22491515

Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand Brustel Y, Auberger P, Tanti JF, Giorgetti Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell cycle arrest through REDD1. Cancer Research. 2011. 71(13): 4366-72. PMID: 21540236

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010. 9(5):1092-9. PMID: 20442309

Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK dependent apoptosis in prostate cancer cells. Autophagy. 2010. 6(5). PMID: 20559023

Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, LeMarchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53 dependent apoptosis in prostate cancer cells. Cancer Research. 2010. 70(6): 2465-75. PMID: 20215500

Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bost F, Cassuto JP, Auberger P. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One. 2009. 4(11): e7889. PMID: 19924252

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008. 27(25): 3576-86. PMID: 18212742